Who we are?
Aomics GmbH is an European based deep-tech healthcare startup, headquartered in Germany. By harnessing the power of publicly available and proprietary big biological data, deep learning, AI and blockchain technologies, our core focus is to develop deep-tech solutions for Personalized medicine and Orphan Drug-Discovery.
We have been developing a personalized immuno-oncology toolkit called Onco-cure. By analyzing tumor microenvironment (TME) dataset Onco-Cure analytical dashboard is aiming at predicting patient specific immune biomarkers and allows oncologists to chose and develop the optimal targeted therapies for the patients. Mission of our proprietary Onco-Cure dashboard is to deliver most insightful approved targeted tailored therapy options to the oncologists within 48 hours.
We develop diagnostics techniques and build drug discovery workflows for rare diseases to tackle huge unmet medical needs. By harnessing the power of biological big data and state-of-the-art artificial intelligence algorithms, multi-omics and cheminformatic techniques, our aim is to effectively reduce the time and cost of the drug discovery process to several folds.
Artificial intelligence & Machine Learning for Drug discovery
We develop powerful AI solutions for drug development and re-positioning. By leveraging AI we identify best compounds, and computationally optimize them for predicted drug targets. We then predict molecular mechanisms by utilizing multi-omics data for a single stop drug development workflow. Our intelligent AI solutions assist in accelerating the drug discovery workflows, and cut down the costs and time to several degrees
How we use Multi-omics data for drug target identification?
We use Omics data to evaluate the following key features for drug targets: the modulation, a target is disease modifying and/or has a proven role in the pathophysiology of a disease; the tissue specificity, a drug target expression is not uniformly distributed throughout the body; and the druggability, a target can be modulated by a drug.
Blockchain for Healthcare
With our blockchain based healthcare application development, we bring clients onto our platform to ensure scalability, security, sustainability and high performance in the drug development workflow. Get in touch with us for establishing a personalised blockchain solution for your Healthcare business
Compounds in Pipeline
Target Indication
Diseases of the nervous system
Congenital malformations, deformations and chromosomal abnormalities
Endocrine, nutritional and metabolic diseases
Diseases of the circulatory system
Atherosclerosis (CVD)
Discovery/Research
Preclinical
Clinical PoC Trials
Clinical Trial
Phase-I
Clinical Trial
Phase-II
Clinical Trial
Phase-III
NDA Filed
(FDA filing)
Technologies under development
Phase-1
Conceptualization
Phase-2
Proof of Concept
Phase-3
Testing & Validation
Phase-4
Launch & Marketing
Phase-5
Scaling & Establishing
Some Numbers
Here are few numbers from our databases
AI processed Scientific Literature/Articles/Patents/White papers
AI extracted and integrated compounds’ data
Pharma & Academic partners
Our AI & Blockchain based Developed models
Artificial Intelligence (AI) predicts the interactions of small-molecules with the multi-omics data for personalised target prediction and drug development
We leverage molecular AI, cheminformatic and molecular docking techniques for identifying the best molecule for an accelerated drug discovery/repositioning workflow
Hit to lead generation and further optimize physicochemical properties of the lead compounds for drug development. Find other similar orphan on-shelf drugs for an efficient drug-repurposing
Aomics GmbH is a German based company founded in 2019 and is headquartered in Frankfurt am Main, Germany. Currently with the interdisciplinary team of experienced healthcare professionals, medicinal chemist and computational biologists, Aomics GmbH is entirely focused on AI & ML-based in-silico drug target identification, drug discovery and personalized medicine solution development.
"AI/Blockchain empowered high quality drug development & drug repurposing pipelines!"
Who We Are
We are a German based company, specialized in the area of drug discovery and drug target identification. By leveraging state-of-the-art artificial intelligence, multi-omics and cheminformatic techniques, we efficiently reduce the time and cost of the drug development process to several folds.
Our Mission
“Make the best use of the state-of-the-art digital technologies, scientific knowledge and resources to accelerate the effective development of new diagnostic techniques and therapeutics for global health”
Our Vision
“To develop highly efficient and effective diagnostic and therapeutic techniques for a healthy future“
Our Values
- Respect
- Honesty
- Innovation
- Integrity & Ethics
- Goal oriented
- Environmental responsibility
- Employee growth
- Customer satisfaction
Our Role
“To serve the patients who are unfortunately suffering with diseases with unmet medical needs by accelerating the development of highly efficient and effective diagnostic and therapeutic techniques“
Our key priority
“Our key priority is to ensure that everyone has access to safe, affordable, fast and efficient solutions to the healthcare problems, especially for the disease areas with huge unmet medical needs”
What We Do
- Biological/healthcare data analytics
- Drug target identification
- Hit-to-lead optimisation of compounds for drug discovery
- Drug development
- Drug repositioning
- Bioinformatics Software Development
- Biological Big data analytics
- Blockchain Solution development
- AI/ML model development
- Tech Support
Would you like to start a project with us?
Reach out on the given number or write us an email for further queries regarding project requirements